AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03032445 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non alcoholic beer
Description: Subject will be asked to consume non alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
Study NCT02145598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
Study NCT02145598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
Study NCT03957876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
Study NCT04280874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 0.5 MG
Description: 0.5mg dinoprostone applied intracervically
Study NCT04280874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly
Description: 2mg dinoprostone applied intravaginally
Study NCT03300778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
Study NCT03300778 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controlled group
Description: 6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
Study NCT01979939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV/ASV/BMS-791325
Study NCT00665769 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypercapnia
Description: transcutaenous CO2 50-60 mm Hg
Study NCT00665769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normocapnia
Description: transcutaneous CO2 35-45 mm Hg
Study NCT03629912 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Socially-Based Exercise Intervention for Older Adults
Description: A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
Study NCT03629912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socially-Based Exercise Intervention for Older Adults
Description: A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
Study NCT04218396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality use during painful bedside procedure
Description: Virtual reality (VR) will be used in addition to standard analgesic practices during painful bedside procedures. A head mounted display (HMD, Oculus Go Model #1KWPH812PN8354) and noise-cancelling headphones (Sony Model #MDRZ110B) will be provided to the patient during the procedure. This unit involves the patient wearing VR goggles, noise-cancelling headphones, and using a smartphone-based program with various applications the patient can choose from for analgesia/relaxation (eg: calming imagery/scenery of nature, activities involving mindfulness, interactive games or guided imagery, music and imagery, exercise imagery...etc). There are numerous, standard applications available for the patient to choose from, and the choice of most optimal application for analgesia, distraction, or anxiolysis will be left to the decision of the patient prior to their procedure.
Study NCT03305185 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Schroth SSE with Bracing
Description: Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
Study NCT03305185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bracing alone
Description: Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
Study NCT03181412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire
Description: Tests from Cincinnati prehospital stroke severity scale (CPSSS) will be carried out by the physician at emergency medical services on telephone call with firemen, paramedics or the emergency medical services team for any stroke suspicion that meets the criteria for inclusion. Emergency department physician will have to follow a standardized questionnaire to complete the different items of the score. The score will not be calculated by emergency department physician and will not influence the orientation and management of patients.~The final diagnosis will be the presence or absence of a large vessel occlusion. This diagnosis will be done on cerebral imaging by a neurologist.
Study NCT02031419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: 2mg or 3 mg administered orally once daily
Study NCT02031419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: 20mg or 30mg administered orally once daily.
Study NCT02031419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once every 28 days
Study NCT02031419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: 2mg or 3mg administered orally once daily.
Study NCT02031419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292
Description: 500 mg twice a day administered orally.
Study NCT02031419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: 20mg or 30mg per day administered orally daily.
Study NCT01786889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood and urine
Description: Blood collection and urine collection after consent of the patient
Study NCT01786889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: The patient complete the questionnaire alone at home
Study NCT01786889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone interview
Description: The patient will be contacted by the CRA for a telephone interview of around one hour
Study NCT03479801 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroid Surgical Methods
Description: Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.
Study NCT01533194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01533194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wild-type Reovirus
Description: Given IV
Study NCT03229291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04755
Description: SM04755 is a small molecule inhibitor of the Wnt pathway.
Study NCT03229291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Same formulation as topical SM04755 solution, without SM04755 included.
Study NCT04602468 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Kaftrio
Description: The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
Study NCT02321163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES new paradigm
Description: stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
Study NCT02321163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES conventional
Description: stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
Study NCT02321163 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NMES no stimulation
Description: Placebo, electrode pad on, no stimulation
Study NCT00323804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
Study NCT00323804 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2b
Description: PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
Study NCT00323804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
Study NCT00323804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin-Placebo
Description: Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
Study NCT01126385 — intervention group
Intervention type: DEVICE
Intervention: DensiProbe Spine
Description: Intraoperative DensiProbe Spine measurements
Study NCT02337855 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
Study NCT04218396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment during painful bedside procedure
Description: Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)
Study NCT02263261 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flex HD Pliable Perforated HADM
Description: Human Acellular Dermal Matrix
Study NCT01665352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP054
Description: Administered orally once daily for 12 weeks.
Study NCT01665352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily for 12 weeks.
Study NCT00774020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 5mg, i.v. single dose
Study NCT04576689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBE-814 70ug
Description: Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
Study NCT04576689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBE-814 140ug
Description: Up to 25 participants will receive IBE-814. Route of administration: intravitreal injection.
Study NCT03855852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft and Collagen membrane
Description: Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
Study NCT03855852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Xenograft and APRF
Description: Placing the implant with APRF and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
Study NCT00869401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally
Study NCT00869401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT00869401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Given orally
Study NCT00869401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00869401 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
Study NCT00869401 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
Study NCT01992562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziconotide
Study NCT01992562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01166477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir and ritonavir
Description: The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
Study NCT03511469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Control Group: Standart rehabilitation
Study NCT03511469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic Group
Description: Concentric group: Standart rehabilitation + isokinetic training
Study NCT00366327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Description: Flex dose (20 or 30 mg)tablet, QD for 1 year
Study NCT01380704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-436
Description: QD Days 1-7
Study NCT01166477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple therapy with ritonavir
Description: The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
Study NCT00589316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Given via central line
Study NCT01380704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: QD Days 1-7
Study NCT01964677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)
Study NCT04928560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SMI
Description: ULTRASOUND
Study NCT03006887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: lenvatinib capsules
Study NCT03006887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab intravenous infusion
Study NCT03489512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (Chloraprep)
Description: Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
Study NCT03489512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B (Clorhexidine 2%)
Description: Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
Study NCT03233126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
Study NCT01300988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant (Emend®) 375 mg daily for 14 days
Study NCT01300988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant placebo
Description: Aprepitant(Emend®) placebo for 14 days
Study NCT04229836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg Solution for Injection
Description: Participants will be treated with tildrakizumab 100 mg.
Study NCT01822613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJM716
Description: LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
Study NCT01822613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
Study NCT01822613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
Study NCT01822613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
Study NCT01822613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
Study NCT03584555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMILE using 120μm cap thickness
Description: The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
Study NCT00589316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03584555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMILE using 140μm cap thickness
Description: The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
Study NCT02337855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Alhydrogel
Description: Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
Study NCT01241071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial treatment
Description: myofascial release techniques of different muscles implicated in low back pain
Study NCT01241071 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A manual sham intervention will be applied to different muscles implicated in low back pain
Study NCT03726931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-Fluorestradiol PET/CT scan
Description: \[18F\]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.
Study NCT03298399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MSCs
Description: Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
Study NCT03298399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MSCs
Description: Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
Study NCT03298399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MSCs
Description: Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10\^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
Study NCT04809155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girl2Girl
Description: The program has a 'core' 7 weeks of daily messages and then a week 'booster' that is delivered 3 months later.
Study NCT01081639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa liquid formulation
Description: Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center